The study aims to improve diabetes prevention, access to care and advocacy through a novel cost-effective nurse-led continuum of care approach that incorporates diabetes prevention, awareness, screening and management for low-income settings, and furthermore utilizes the endeavor to advocate for establishing standard diabetes program in Nepal.
The purpose of this study will be to improve diabetes prevention, access to care and advocacy through a novel cost-effective nurse-led continuum of care approach that incorporates diabetes prevention, awareness, screening and management for low-income settings, and furthermore utilizes the endeavor to advocate for establishing standard diabetes program in Nepal. We will conduct a two-arm, open-masked stratified cluster randomized controlled trial of a NUrse-led COntinuum of care for people with diabetes and pre-diabetes (NUCOD), with primary care centers (Outreach centers and Government health posts) as a unit of randomization. NUCOD will be delivered through the trained diabetes nurses in the community to the intervention group and the outcomes will be compared to the enhanced usual-treatment group at 6 and 12 months of the intervention. The primary outcome will be change in glycated hemoglobin (HbA1c) level among diabetes and progression to type 2 diabetes among pre-diabetes, and implementation outcomes measured using the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework. Outcomes will be analyzed on an intention to treat basis. The results of this trial will provide information about the effectiveness of the NUCOD program in improving clinical outcomes for diabetes and pre-diabetes individuals, and implementation outcomes for the organization.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
1,236
This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
Change in Glycated Hemoglobin (HbA1c) level
The HbA1c will be measured using Boronate affinity chromatography (Axis-Shield, Norway)
Time frame: Baseline, 6 months, 12 months
Change in the incidence of diabetes among individuals with pre-diabetes
Electronic Health Record will be used to measure the incidence of diabetes
Time frame: 6 months, 12 months
Change in Blood Pressure
The blood pressure will be measured using mean of three measurements of systolic and diastolic blood pressure, using a Microlife automatic blood pressure measuring device
Time frame: Baseline, 6 months, 12 months
Change in lipid profile levels (HDL, LDL, Triglycerides, Total cholesterol)
LDL and HDL will be measured using the elimination method (Dialab, Austria); triglyceride using GPO-PAP (Dialab, Austria); and total cholesterol using CHOD-PAP (Dialab, Austria)
Time frame: Baseline, 6 months, 12 months
Change in Body Mass Index
Body Mass Index will be calculated as weight in kilograms divided by height in meters squared
Time frame: Baseline, 6 months, 12 months
Change in the "Reach" of people participating in the program
Reach will be measured by the number of people participating in the program divided by the number of people eligible to be recruited into the program
Time frame: 6 months, 12 months
Change in the "Adoption at the patient level" measured by the Summary of Diabetes Self-Care Activities Scale
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Adoption at the patient level will be measured by the proportion of people adherent to the clinical advice in lifestyle and self-care. These will be measured by the self-reported Summary of Diabetes Self-Care Activities scale. Five areas are assessed by the scale: Diet, Exercise, Blood-glucose testing, Foot care, and Smoking status. Scale of 0-7 is used. Higher the score better is the outcome.
Time frame: Baseline, 6 months, 12 months
Change in the "Adoption at the patient level" measured by the Diabetes Treatment Satisfaction Questionnaire
The Diabetes Treatment Satisfaction Questionnaire will be used to measure patient perception of the treatment. It is composed of eight questions, each of which is scored by patients on a scale ranging from zero (e.g., "very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient"). More satisfied the patient, better is the outcome.
Time frame: Baseline, 6 months, 12 months
Change in the "Adoption at the clinic level"
Adoption at the clinic level will be measured by a number of participants served using health records and examining nurses' adoption of intervention program through interviews
Time frame: 6 months, 12 months